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Summary 
Osteoarthritis (OA) is the most common articular heumatic disease. Practice guidelines have been developed to assist 
the practitioner in the care of patients with hip and knee OA. The guidelines divide the treatment strategy into 
nonpharmacologic and pharmacologic modalities. The nonpharmacologic or nonmedicinal pproaches include patient 
education, psychosocial interventions, physical and surgical measures. Each of these are as important as the 
pharmacologic or medicinal measures. Medicinal measures can be subdivided into symptomatic therapy and disease 
modifying therapy. Even though all present herapies are aimed at symptoms, experimental therapies are being 
developed to alter the disease process. 
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Introduction 
OSTEOARTHRITIS (OA) is a disease that involves 
articular cartilage and whose end result is 
failure of the joint as an organ system. OA is the 
most common articular rheumatic disease. Its 
prevalence has been estimated to be as much as 
12% of the U.S. population and is linked 
to advancing age [1]. Seventy five per cent of 
persons over the age of 70 are said to have 
radiographic OA at least at one site [2]. Training 
physicians in efficient and cost effective manage- 
ment strategies for OA is of importance. 
At present, therapy is directed at relief of 
symptoms. Guidelines for the management of OA of 
the knee and hip in the United States have been 
recently published by the American College of 
Rheumatology [3, 4]. Below we outline the 
published practice guidelines, integrating 
them with new and other agents used in other 
countries. 
After a diagnosis of OA is established, the 
source(s) of symptoms in each patient should be 
carefully sought through physical examination 
and appropriate testing. The main symptom in OA 
is pain, which has many potential causes [5]. 
Identif ication of the cause of pain in the individual 
Supplement sponsored by IBSA (Switzerland)/Laboratoires 
GENEVRIER (France). 
patient may lead to prompt, effective symptom 
therapy. 
Nonpharmacologic therapy 
PREVENTIVE THERAPY 
OA may be averted or mitigated by identifying 
individuals at risk for developing OA. Obesity is a 
risk factor for OA of the knees in women and is 
probably a risk factor for OA of the hip and knee 
in men and women [6, 7]. Modest weight loss 
(5 10kg) may be of benefit in reducing pain. 
Reduction in occupational trauma may also be of 
value. 
SYMPTOMS 
Most symptomatic therapy for OA is directed at 
pain. The approach should be multidisciplinary, 
and should combine therapeutic measures. 
Physical measures include exercise, supportive 
devices and orthotics, thermal modalities, and 
modification of the activities of daily living as 
necessary. Patients need to maintain a balance of 
rest and exercise. The exercise should improve 
strength (anaerobic: e.g. isotonic, isometric) and 
endurance (aerobic: e.g. walking, swimming). 
Support devices may include a cane, crutch, 
orthotics, brace, etc. Thermal applications hould 
be modest and intermittent as they are intended to 
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reduce pain and muscle spasm, enhancing the 
exercise program. 
SURGICAL INTERVENTIONS 
These interventions include arthroscopic sur- 
gery, osteotomies, and joint replacement. Despite 
the great success of total knee and total hip 
arthroplasties, urgical intervention represents a
failure of the medical regimen and should be 
reserved for those patients with uncontrolled pain, 
most of whom have severe restrictions on their 
daily activities. 
Pharmaco log ic  therapy 
SYMPTOM THERAPY 
Medication-based therapy can be subdivided 
into nonanti-inflammatory analgesic agents, 
topical agents, nonsteroidal anti-inflammatory 
drugs (NSAIDs), narcotic analgesics, antispasmod- 
ics, intra-articular agents. Nonanti-inflammatory 
analgesics, such as aeetaminophen (paracetamol) 
have become the first line of treatment for 
OA. Many patients can be managed with 
acetaminophen as their only oral medication. 
Topical agents have gained popularity. Capsa- 
icin has shown a modest, but statistical benefit in 
double blind trials. Topical nonsteroidal anti- 
inflammatory (NSAID) agents are available in 
many countries; more information is needed in 
double-blind trials to establish their effectiveness. 
NSAIDs are the most commonly prescribed 
medications for the treatment of OA. They work 
through generally nonspecific inhibition of cyclo- 
oxygenases 1 and 2. Initial dosing should be low, 
as analgesia can be achieved at relatively low 
doses. 
Misoprostol, a prostaglandin analogue, may be a 
useful adjunct in these patients by reducing the 
incidence of gastric adverse events, especially in 
those with pre-existing astrointestinal symptoms, 
the elderly and those with significant comorbidity. 
The development of selective cyclo-oxygenase 2 
inhibitors may mitigate the gastrointestinal prob- 
lems with these agents, but do not seem to provide 
any added beneficial effect. 
Narcotic analgesics (or derivatives such as 
propoxyphene) have been used with success in 
patients with OA and significant pain not 
responsive to other OA drugs. New approaches to 
analgesia are being developed. One of the newer 
agents, tramadol, is a dual action analgesic with 
effects on both opioid and alpha adrenergic 
receptor pathways. 
Although as yet unproven, antidepressants may 
be useful adjunct agents, particularly those with 
both adrenergic and serotonin agonist activity. 
There are sulfated glycosaminoglycans, such as 
chondroitin sulfate and glucosamine, available in 
many countries with apparent pain-relieving 
properties. Tricyclic antidepressants may be of 
value, especially in those patients with sleep 
disturbances and fibromyalgia-like symptoms. 
There is occasional Value in the use of 
antispasmodics, mostly centrally acting drugs with 
strong sedative properties. Local injections 
of lidocaine can be useful in relieving the pain of 
muscle spasm. 
Intra-articular therapy may include depocorti- 
costeroids, hyaluronate and beta-emitting radio- 
nuclides. Depocorticosteroids are safe and appear 
of value when active inflammation is present. It is 
recommended that a single joint be not injected 
more than three or four times a year. Hyaluronate 
has been proven of value in a subset of patients 
with painful OA of the knee, but do not seem to 
effect the volume of the synovial effusion. Medical 
synovectomy with radioactive isotopes eems to be 
of value in those occasional patients with large 
refractory synovial effusions. Systemic glucocorti- 
coids are not a therapeutic option for OA. 
There is increasing information that sulfated 
glyeosaminoglycans, such as ehondroitin sulfate 
and glueosamine, have pain-relieving properties. 
Tidal joint lavage (irrigation) may be of value in 
the presence of persistent inflammation, especially 
in the presence of large synovial effusions. 
DISEASE (STRUCTURE) MODIFICATION 
Many agents are being investigated for the 
potential of disease modification, including several 
agents listed above. Sulfated glycosaminoglycans, 
doxycycline, metalloproteinase inhibitors, growth 
factors and cell/tissue implants are being 
examined. 
UNPROVEN REMEDIES 
As long as there is no established remittive agent 
for OA, multiple unproven remedies will be used. 
Diet, herbs, copper bracelets, acupuncture, and 
many other popular therapies need to undergo 
appropriate clinical research, as some of them may 
have true clinical value. 
Conc lus ions  
In the absence of a program that can alter the 
course of OA, symptom relief (mostly pain) remains 
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the object ive of present  day therapy. Effective 
therapy will combine physical,  medicinal,  psycho- 
logical and surgical  approaches in a methodical  and 
stepwise fashion. 
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